Skip to main content

Table 3 Primary outcomes, change from baseline, intention-to-treat

From: Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]

  Placebo (n = 16) Fluvoxamine (n = 17) P-value
  Day 14 Day 42 Day 70 Day 14 Day 42 Day 70 Day 14 Day 42 Day 70
VAS Fatigue -1.3 -0.6 -0.55 -0.3 -0.4 -0.35 0.31 0.51 0.51
FFSS
   Physical Domain -2.0 -3.5 -4.0 0 -2.5 0 0.31 0.40 0.12
   Cognitive Domain -1.5 1.0 0 -1.0 -1.0 0 0.69 0.85 0.60
   Social Domain -3.0 -3.5 -2.0 -3.0 -4.0 -1.5 0.66 0.93 0.93
MFI
   General Fatigue -2.0 0 0 0 0 -1.0 0.10 0.62 0.87
   Physical Fatigue 0 0 0 0 1.0 1.0 0.92 0.73 0.44
   Reduction Activity 0.5 -1.0 0 1.0 -0.5 1.0 0.20 0.56 0.13
   Reduction Motivation -1.0 0 -1.0 1.0 -0.5 1.0 0.08 0.94 0.71
   Mental Fatigue -1.0 -0.5 0 0 0 0 0.06 0.35 0.89
  1. Results are expressed as median differences in scores compared to baseline.